Zacks Small Cap Issues Negative Forecast for ARWR Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Equities research analysts at Zacks Small Cap dropped their Q2 2025 earnings estimates for Arrowhead Pharmaceuticals in a research report issued on Wednesday, February 12th. Zacks Small Cap analyst D. Bautz now forecasts that the biotechnology company will post earnings of ($1.01) per share for the quarter, down from their prior estimate of ($0.97). The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.40) per share. Zacks Small Cap also issued estimates for Arrowhead Pharmaceuticals’ Q3 2025 earnings at ($1.01) EPS, FY2025 earnings at ($4.39) EPS, FY2026 earnings at ($3.05) EPS and FY2027 earnings at ($2.75) EPS.

Other equities analysts also recently issued research reports about the stock. B. Riley reaffirmed a “buy” rating and issued a $38.00 price objective (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. Piper Sandler decreased their price objective on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. HC Wainwright reissued a “buy” rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a report on Wednesday. Finally, Sanford C. Bernstein reduced their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a report on Friday, November 29th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $41.44.

Arrowhead Pharmaceuticals Stock Performance

Arrowhead Pharmaceuticals stock opened at $19.95 on Friday. The company has a market cap of $2.50 billion, a PE ratio of -3.97 and a beta of 0.95. The company has a fifty day moving average price of $20.00 and a two-hundred day moving average price of $21.10. The company has a debt-to-equity ratio of 2.06, a current ratio of 6.74 and a quick ratio of 6.74. Arrowhead Pharmaceuticals has a 12 month low of $17.05 and a 12 month high of $36.72.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97).

Insiders Place Their Bets

In other Arrowhead Pharmaceuticals news, Director Adeoye Y. Olukotun sold 2,850 shares of the business’s stock in a transaction dated Friday, December 27th. The shares were sold at an average price of $20.00, for a total value of $57,000.00. Following the sale, the director now directly owns 36,740 shares in the company, valued at approximately $734,800. The trade was a 7.20 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Christopher Richard Anzalone sold 11,520 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $19.05, for a total value of $219,456.00. Following the sale, the chief executive officer now owns 3,764,252 shares in the company, valued at approximately $71,709,000.60. The trade was a 0.31 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 147,432 shares of company stock worth $2,957,986. 4.30% of the stock is owned by corporate insiders.

Institutional Trading of Arrowhead Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. R Squared Ltd acquired a new stake in Arrowhead Pharmaceuticals during the 4th quarter worth about $38,000. Values First Advisors Inc. acquired a new stake in Arrowhead Pharmaceuticals during the 3rd quarter worth about $52,000. Van ECK Associates Corp raised its holdings in Arrowhead Pharmaceuticals by 72.3% during the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock worth $56,000 after buying an additional 1,250 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Arrowhead Pharmaceuticals by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock worth $88,000 after buying an additional 788 shares during the period. Finally, KBC Group NV increased its holdings in shares of Arrowhead Pharmaceuticals by 45.9% in the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 1,644 shares during the period. Institutional investors and hedge funds own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.